EX-23.1 2 chrs-20251113xex23d1.htm EX-23.1

​

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

| (1) | Registration Statements (Form S-3 Nos. 333-208625, 333-220590, 333-222698, and 333-268252) of Coherus Oncology, Inc.,

​

| (2) | Registration Statement (Form S-8 No. 333-200593) pertaining to the BioGenerics, Inc. 2010 Equity Incentive Plan, as amended, the Coherus Oncology, Inc. 2014 Equity Incentive Award Plan, and the Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan,

​

| (3) | Registration Statements (Form S-8 Nos. 333-203356, 333-209936, 333-216679, 333-222700, 333-229480, 333-236068, 333-251876, and 333-262134) pertaining to the Coherus Oncology, Inc. 2014 Equity Incentive Award Plan and the Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan,

​

| (4) | Registration Statements (Form S-8 Nos. 333-213077, 333-225616, 333-228274, 333-229479, 333-231329, 333-234601, 333-236065, 333-251877, and 333-262941) pertaining to the 2016 Employment Commencement Incentive Plan of Coherus Oncology, Inc.,

​

| (5) | Registration Statements (Form S-8 Nos. 333-269291 and 333-278314) pertaining to the Coherus Oncology, Inc. 2014 Equity Incentive Award Plan, and

​

| (6) | Registration Statement (Form S-8 No. 333-281394) pertaining to the Coherus Oncology, Inc. Amended and Restated 2014 Equity Incentive Award Plan;

of our report dated March 17, 2025 (except for Note 6, as to which the date is November 13, 2025), with respect to the consolidated financial statements of Coherus Oncology, Inc., included in this Current Report on Form 8-K.

/s/ Ernst & Young LLP

San Mateo, California

November 13, 202 5